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Abstract. We conducted an open-label, randomized clinical trial to assess parasite clearance times (PCT) and the efficacy
of 4 mg/kg (group 1, n = 22) and 2 mg/kg (group 2, n = 22) of oral artesunate for three days followed by artemether-
lumefantrine in patients with uncomplicated Plasmodium falciparum malaria at Xepon Interdistrict Hospital, Savannakhet
Province in southern Laos. Slides were read in duplicate. The overall mean (95% confidence interval; range) PCT in
hours was 23.2 (21.2–25.3; 12–46) and 22.4 (20.3–24.5; 12–46) for the first and second microscopists, respectively (P = 0.57).
Ten (23%) patients remained parasitemic on day 1 after treatment (4 [18%] in group 1 and 6 [27%] in group 2; P = 0.47).
No patient had patent asexual parasitemia on the second and third days of treatment. The 42-day polymerase chain
reaction–corrected cure rates were 100% in both treatment groups. Serious adverse events did not develop during or
after treatment in any patients. In conclusion, no evidence of P. falciparum in vivo resistance to artesunate was found in
southern Laos.
INTRODUCTION
Parasitologic responses to artesunate-containing treatment
regimens for uncomplicated Plasmodium falciparum malaria
have recently been shown to be slower in western Cambodia
than elsewhere in the world. Both prolonged parasite clear-
ance times (PCTs) and unusually high treatment failure rates
after artesunate-mefloquine have been reported despite ade-
quate antimalarial blood concentrations.
1–3 Although poor
responses to artesunate have been described,
4 the recent
reports suggest a consistent focal problem. There is also evi-
dence for slightly prolonged PCTs and higher treatment
failure rates after artesunate-mefloquine on the Thailand/
Myanmar (Burma) border.
5,6 In pooled data from 18,699
patients who received artemisinin derivatives, of those who
were non-hyperparasitemic, only 1.8–5% had PCTs > 72 hours.
7
Because the rate of parasite clearance is a good pharmacody-
namic measure of efficacy of artemisinin-related compounds,
8,9
slow parasite clearance could indicate the emergence of signif-
icant resistance, although host immunity and antimalarial phar-
macokinetic differences could confound the relationship.
Artemisinin-based combination therapies (ACTs) are cen-
tral to current malaria treatment strategies,
10 and the spread of
malaria parasites with significant resistance to the artemisinin
derivatives would be a public health disaster, especially if they
contaminated Africa. There is therefore an urgent need to
investigate rapidly whether there is any evidence of resis-
tance to artemisinin derivatives in southern Laos, which is
only approximately 400 km from the Thailand/Cambodia bor-
der area of artemisinin resistance/tolerance. Although ACTs
were introduced as national policy by the Government of Laos
in 2005, artesunate monotherapy with variable patient adher-
ence has been used since 1999. In addition, counterfeit
artesunate containing subtherapeutic quantities of artemisinin
has been reported in the area.
11
The mean (95% confidence interval [CI]) PCT in a series of
861 patients with P. falciparum malaria recruited in three tri-
als in southern Laos treated with artemisinin derivatives
(artesunate plus mefloquine, n = 316), artemether-lumefantrine
(n = 238), and dihydroartemisinin-piperaquine (n = 307) during
2002–2008 was 1.89 (1.86–1.92) days (range = 1–4 days). Only
2 (0.23%) patients had PCTs > 3 days (4 days) and 30 (3.48%)
had PCTs > 2d a y s .
12–14 These results are reassuring. How-
ever, these studies involved daily blood sampling for parasite
counts, rather than six hourly counts, which would be required
to detect anything other than gross changes in PCT. Further-
more, the last available data were collected in 2008. We there-
fore conducted a randomized clinical trial comparing oral
artesunate (2 mg/kg/day versus 4 mg/kg/day for 3 days) fol-
lowed by a 3-day treatment course of artemether-lumefantrine
to estimate the current efficacy of the drug for uncomplicated
P. falciparum malaria in southern Laos.
MATERIALS AND METHODS
Study site, patients, and clinical procedures. The study was
conducted during June–September 2010 at Xepon (30 beds)
Inter-District Hospital (16.69° N, 106.20° E, 208 meters above
sea level) in southern Savannakhet Province, Laos, near the
Laos/Vietnam border, approximately 665 km southeast of
Vientiane, the capital of Laos. Xepon (88 villages, population =
48,000) is inhabited predominantly by rice farmers of the Lao
Theung ethnic groups. Malaria transmission is seasonal with a
peak during the rainy months of July and August.
Under the null hypothesis that the proportion of patients
parasitemic on day 3 after ACT treatment is < 3%, the proba-
bility of finding more than six patients with a positive parasite
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403count on day 3 is P < 0.05 if 20 patients are recruited in
each arm.
7
Patients with uncomplicated P. falciparum malaria were
enrolled in the study provided that they gave fully informed
written consent, had P. falciparum mono-infections with
an asexual parasite density of 10,000–175,000 parasites/µL,
were ³ 10 years of age (and for female patients were before
menarche or after menopause), had a tympanic temperature
³ 37.5°C or history of fever during the previous 24 hours,
were able to swallow oral medication, and were willing to stay
in the hospital until parasite clearance and complete 42-days
of follow up. Patients were excluded if they had danger signs
or severe P. falciparum malaria,
15 severe malnutrition, febrile
conditions caused by diseases other than malaria or other
known underlying chronic or severe diseases, had received
antimalarial drugs in the previous 48 hours, had a history of
hypersensitivity reactions or contraindications to study medi-
cines, or had had a splenectomy.
On admission, blood samples were taken for parasite count
and hematocrit, and three blood spots were collected onto
filter paper for polymerase chain reaction (PCR) genotyping
in the event of reappearance of P. falciparum during follow-
up.
12–14 The PCR amplification was performed on paired
samples for parasite genotyping to distinguish between
reinfection and recrudescence by using three parasite loci
(merozoite surface protein 1, merozoite surface protein 2,
and glutamate-rich protein).
16
Patients who met the enrollment criteria were randomized
(the treatment allocation was kept in a sealed opaque enve-
lope, which was opened only after the decision to recruit had
been made) to oral artesunate (Batch AS091001; Guilin
Pharmaceutical Company, Shanghai, China), either 4 mg/kg/day
(group 1) or 2 mg/kg/day (group 2) for 3 days, followed by the
ACT recommended by the national treatment guidelines;
artemether-lumefantrine (20/120 mg) (Coartem
Ò,N o v a r t i s ,
Basel, Switzerland), 1 dose twice a day for three days. Dosing
by body weight was 1 tablet if < 15 kg, 2 tablets if 15–24 kg,
3 tablets if 25–34 kg, and 4 tablets if ³ 35 kg. The artesunate
used was quality controlled by Research Institute for Indus-
trial Pharmacy (Potchefstroom, South Africa). Drug adminis-
tration was directly observed and if vomiting occurred within
one hour of dosing, medication was re-administered. All anti-
malarial drugs were stored at 6–10°C.
Tympanic temperature, parasite counts, and hematocrit
were measured every 6 hours until parasite clearance and
then daily until discharge and on days 7, 14, 21, 28, 35, and
42. A standard physical examination was performed on day 0
(before drug administration), and the patients were reviewed
daily until parasites cleared, then weekly for 42 days from
the start of treatment, or at other times if he or she felt
unwell. At each visit, finger prick blood was taken for a
malaria smear and hematocrit. Three blood spots were col-
lected onto filter paper from those with reappearance of
asexual parasitemia. Patients with P. falciparum recurrence
were re-treated with artesunate, 4 mg/kg/day for 7 days plus
mefloquine, 15 mg base/kg on day 1 and 10 mg base/kg on
day 2 and followed up for an additional 42 days. Those who
had P. vivax appearance during follow-up were treated with
chloroquine (25 mg base/kg) for 3 days and further followed-up.
The incidence of any adverse event was recorded.
Written informed consent was obtained from all partici-
pants. Ethical clearance for the study was granted by the Lao
National Ethics Committee for Health Research, the Oxford
University Tropical Medicine Research Ethics Committee,
United Kingdom and the Research Ethics Review Committee
of the World Health Organization. The trial registration num-
ber is ISRCTN12741594. The trial was monitored by the
Clinical Trials Support Group of Mahidol-Oxford Tropical
Medicine Research Unit, Bangkok, Thailand.
Laboratory investigations and outcome measures. Parasite
counts for thick and thin blood films, stained with Field’s
stain, and hematocrit were determined every six hours until
parasite clearance for two consecutive slides and then daily
until patients’ hospital discharge and weekly after day 7.
12–14
Two qualified microscopists (Level 1/expert malaria micros-
copists certified by the World Health Organization, Geneva,
Switzerland, and the Asian Collaborative Training Network
for Malaria, Manila, the Philippines) read all the slides inde-
pendently. The PCR amplification was performed on paired
samples for parasite genotyping to distinguish between rein-
fection and recrudescence.
17
The primary study outcome was the number of patients
with PCT > 72 hours. The PCT was defined as the time in
hours from the first treatment dose to the first of two con-
secutive thick blood films that were negative for asexual
P. falciparum parasites after checking ³ 200 oil-immersion
fields. The secondary outcomes were the PCR-corrected ade-
quate clinical and parasitologic response at day 42,
18 fever
clearance times, time in hours from the start of treatment at
which the tympanic temperature first decreased to < 37.5°C
and remained below 37.5°C for 48 hours), the frequency of
adverse events and fractional changes in hematocrit after
antimalarial treatment.
Statistical analysis. Data were entered into a database by
double independent data entry and cross-validated. Data were
analyzed by using SPSS version 11.0 (SPSS Inc., Chicago, IL).
Comparisons between the two treatment groups were made by
using the Mann–Whitney U test, Student’s t-test, chi-square
test, and Fisher’s exact test as appropriate. Parasite clearance
rates were calculated as the slope of the linear portion of the
log-normalized parasite clearance curve, and this was used to
estimate the times to clearance of 50% and 90% of the para-
site load for each patient. The parasite reduction ratio was
defined as the proportion of admission parasites that remained
after 24 hours.
RESULTS
Patient screening and enrollment are shown in Figure 1.
Baseline characteristics of the two study groups were similar
(Table 1). The male preponderance reflects the decision of
the Institutional Review Board of the World Health Organi-
zation that women of childbearing age could not be recruited.
Because three patients were found after randomization to
have taken antimalarial drugs before recruitment, four addi-
tional patients were randomized so that 20 patients without
prior antimalarial drug use were recruited into each arm. All
patients (100%) completed 42 days of follow-up (Figure 1).
Admission parasitemia, parasite reading, and clearance. The
overall admission geometric mean (95% CI) parasitemia/µL
was 45,113 (35,473–57,372) (Table 1). The percentage (95%
CI) agreement in reading slides (as positive or negative)
between the first and second microscopists was 96.4% (94.4–
97.6%) (k = 0.92), which is classified as very good agreement.
19
404 MAYXAY AND OTHERSThe slide-reading results from the first microscopist were used
to calculate the slopes and parasite reduction ratios (Figure 2).
The overall mean (95% CI; range) PCTs (hours) were
23.2 (21.2–25.3; 12–46) and 22.4 (20.3–24.5; 12–46) for the
first and second microscopists, respectively (P = 0.57).
Ten (23%) patients remained parasitemic on day 1 after
treatment (4 [18%] and 6 [27%] in group 1 and group 2, respec-
tively; P = 0.47). No patient had patent asexual parasitemia on
Figure 1. Participants in a study comparing 4 mg/kg/day versus 2 mg/kg/day of oral artesunate for treatment of Plasmodium falciparum
Malaria in Laos. Pf = P. falciparum; Pv = P. vivax; PCR = polymerase chain reaction.
Table 1
Admission demographics and clinical and laboratory details for patients enrolled in a study comparing 4 mg/kg/day versus 2 mg/kg/day of oral
artesunate for three days followed by three days of artemether-lumefantrine for treatment of Plasmodium falciparum malaria in Laos*
Variable
Treatment groups
All (n = 44) 4 mg/kg/day (n = 22) 2 mg/kg/day (n = 22)
Male sex, no (%) 38 (86) 20 (91) 18 (82)
Age, years, median (range) 28 (11–66) 28 (11–66) 25 (12–65)
Height, cm 155.4 (151.6–159.2) 158.9 (155.6–162.2) 151.9 (145.1–158.7)
Body weight, kg 49.8 (45.8–53.8) 51.7 (46.7–56.7) 47.9 (41.5–54.4)
Tympanic temperature, °C 38.5 (38.1–38.9) 38.3 (37.8–38.8) 38.7 (38.1–39.2)
Patients without fever on admission, no. (%) 9 (20) 6 (27) 3 (14)
Systolic blood pressure, mm Hg 109.1 (106.2–112.1) 108.6 (104.7–112.6) 109.5 (104.9–114.2)
Diastolic blood pressure, mm Hg 77.0 (74.5–79.6) 76.8 (73.1–80.5) 77.3 (73.4–81.2)
Pulse, beats/min 86.8 (84.6–88.9) 86.2 (82.4–89.9) 87.4 (84.8–89.9)
Respiratory rate/min 24.3 (23.3–25.4) 24.3 (22.7–25.8) 24.4 (22.8–25.9)
Splenomegaly, no. (%) patients 2 (4.5) 1 (4.5) 1 (4.5)
Hepatomegaly, no. (%) patients 1 (2.3) 0 1 (4.5)
Parasitemia, geometric mean (95% CI) parasites/µL 45,113 (35,473–57,372) 45,112 (30,853–65,948) 45,123 (32,509–62,632)
Hematocrit, % 42.1 (40.4–43.8) 42.9 (40.1–45.7) 42.1 (40.4–43.8)
*Values are mean (95% confidence interval) unless otherwise indicated.
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PCT (hours) was significantly shorter in group 1 than in
group 2 (21.0 [18.7–23.3] versus 25.4 [22.1–28.8]; P = 0.029)
for slides read by the first microscopist but not for the second
microscopist (P = 0.10). For the 41 patients with no evi-
dence of prior antimalarial drug use, the mean (95% CI; range)
PCT (hours) was 23.6 (21.5–25.7; 14–46) and 22.5 (20.3–24.6;
12–46) for the first and second microscopists, respectively.
Using the results of slide reading from the first microscopist,
we determined that the estimated overall median (range) time
(hours) to 50% parasitemia and the clearance rate of parasites
was 5.1 (0.6–17.8) and 0.16 (0.09–0.26), respectively (Table 2).
The mean [95% CI] PCT (hours) was longer in those £ 15
years of age (n = 7) than in those > 15 years of age (n = 37),
but this was not statistically significant (26.1 [17.5–34.6] versus
22.7 [20.6–24.8]; P = 0.23). None of the patients had patent
gametocytemia on admission, and gametocytemia did not
develop after treatment.
Cure rates, fever clearance, and change in hematocrit. The
mean (95% CI) multiplicity of infection was 1.33 (0.92–1.75)
and this was found in 30% of the total samples for this study.
One patient in group 2 had P. falciparum reappearance at day
30 and the PCR analysis indicated that this was a reinfection.
Therefore, the 42-days PCR-corrected cure rates were 100%
in both treatment groups. Two patients (one in each group)
had P. vivax appearance at day 35 and day 27 and were suc-
cessfully treated with oral chloroquine.
All patients had a history of fever during the 24 hours
before enrollment and 35 (79.5%) of them were febrile at
presentation, as defined by a tympanic temperature ³ 37.5°C.
After treatment, all patients were afebrile by day 2. The
overall mean (95% CI) fever clearance time was 20.0 (16.2–
23.8) hours, and this finding was not significantly different
between the two groups. The admission mean (95% CI)
hematocrit was significantly higher than those on other days
(P < 0.001), but the fractional changes in hematocrit from
admission over time did not differ significantly between the
groups (Table 2).
Adverse events. Severe malaria or serious adverse events
did not develop in any patients during or after treatment. The
frequency of patients with symptoms and signs, before treatment,
that may subsequently be confused with drug adverse events
were similar between the two groups (Table 3).
Figure 2. Parasite clearance curves for Lao patients compared
with those from previous studies conducted in Pailin, Cambodia and
Wang Pha, Thailand.
3 Lao data are log10-normalized median parasite
densities over time among the 22 patients in each treatment group.
Error bars indicate 50% of interquartile ranges (IQR).
Table 2
Outcome measures for the treatment of patients enrolled in a study comparing 4 mg/kg/day versus 2 mg/kg/day of oral artesunate for treatment of
Plasmodium falciparum malaria in Laos*
Variable
Treatment groups
P All (n = 44) 4 mg/kg/day (n = 22) 2 mg/kg/day (n = 22)
42-day cure rate, no. (%) patients 44 (100) 22 (100) 22 (100) –
Fever clearance time, mean hours 20.0 (16.2–23.8) 20.6 (15.7–25.5) 19.5 (13.3–25.7) 0.77
Patients remained febrile at day 1, no. (%) 7 (16%) 2 (9%) 5 (23) 0.41
Patients remained febrile at day 2, no. (%) 0 0 0 –
Parasite clearance time by first microscopist 23.2 (21.2–25.3) 21.0 (18.7–23.3) 25.4 (22.1–28.8) 0.029
Parasite clearance time by second microscopist 22.4 (20.3–24.5) 20.8 (18.4–23.1) 24.1 (20.6–27.6) 0.10
Positive parasitemia at day 1, no. (%) patients 10 (23) 4 (18) 6 (27) 0.47
Positive parasitemia at day 2, no. (%) patients 0 0 0 –
Time to 50% clearance of parasite density, hours 5.1 (0.6–17.8) 4.4 (0.6–15.8) 6.4 (1.2–17.8) 0.01
Time to 90% clearance of parasite density, hours 9.7 (4.5–28.1) 9.0 (4.5–18.1) 11.6 (5.2–28.1) 0.02
Parasite reduction ratio at 24 hours 0 (0–10) 0 (0–0.6) 0 (0–10) 0.38
Parasite clearance rate (slope of curve for log10-normalized parasite clearance)† 0.16 (0.09–0.26) 0.17 (0.13–0.26) 0.16 (0.09–0.22) 0.02
P. vivax appearance after treatment of P. falciparum, no. (%) patients 2 (4.5) 1 (4.5) 1 (4.5) –
Hematocrit
Day 0 42.1 (40.4–43.8) 42.9 (40.1–45.7)‡ 42.1 (40.4–43.8)‡ 0.36
Day 7 37.1 (35.6–38.5) 37.4 (35.3–39.5) 37.1 (35.6–38.5) 0.63
Day 14 37.4 (35.9–38.8) 37.7 (35.4–39.9) 37.4 (35.9–38.8) 0.67
Day 21 38.3 (36.9–39.7) 38.5 (36.6–40.4) 38.3 (36.9–39.7) 0.75
Day 28 38.8 (37.6–39.9) 38.7 (37.0–40.4) 38.8 (37.6–39.9) 0.90
Day 35 39.2 (37.9–40.4) 39.7 (37.9–41.4) 39.2 (37.9–40.4) 0.39
Day 42 39.5 (38.3–40.7) 39.7 (38.0–41.4) 39.5 (38.3–40.7) 0.76
*Values are mean (95% confidence interval) unless otherwise indicated.
†Defined as the slope of linear portion of the log10-normalized parasite clearance curve.
‡Significant difference from other days (P < 0.001).
406 MAYXAY AND OTHERSDISCUSSION
The study showed no evidence of P. falciparum resistance
to artesunate, as defined by prolonged PCT, approximately
400 km, as the crow-flies, from the focus of P. falciparum resis-
tance to artemisinin derivatives in western Cambodia. None of
the study patients were parasitemic on days 2 or 3 after treat-
ment with either 4 mg/kg/day or 2 mg/kg/day of oral artesunate
for 3 days, which is reassuring for the continued use of the
currently recommended ACT regimen in Laos. The mean PCT
in southern Laos (approximately 23 hours) is much shorter than
that found in Pailin in western Cambodia (approximately
84 hours) and in Wang Pha in northwestern Thailand (48 hours)
(Figure 2),
3 although the admission parasitemias in Laos were
higher than those in Wang Pha but similar to those in Pailin.
In contrast to patients in Laos, 55% of patients in Pailin
and 8% in Wang Pha remained parasitemic at day 3 after
starting treatment.
This study suggests that P. falciparum parasites resistant
to artemisinins have not spread from the western Cambodia
to the southern Laos/Vietnam border area. Importantly,
artemisinin-resistant parasites have not been described from
eastern Cambodia, south of Laos, and there is currently rela-
tively little recorded population flow across the southern Lao/
eastern Cambodia border (approximately 1,500–3,000 persons/
year compared with an estimated 30,000–100,000 persons/year
who moved across the southern Laos/Vietnam border) (data
for 2005–2009).
20 With improvement of road communications,
population flow across the Laos/Cambodia border will inevita-
bly increase. Oral artesunate monotherapy, including fake or
substandard quality artesunate, were in use in southern Laos
for at least six years before 2005 when the Lao Government
changed the national policy for uncomplicated P. falciparum
malaria treatment to ACT.11
The absence of artemisinin resistant P. falciparum from
at least one site in southern Laos is reassuring. However,
prevention of conditions that would facilitate survival of
artemisinin-resistant parasites in southern Laos, such as
removal of all artesunate monotherapy, ensuring that ACTs
are of good quality and the encouragement of adherence to
correct dosage regimens, are urgently needed. Regular moni-
toring of the clinical efficacy of artemisinin-derivatives in
southern Laos, especially closer to the Cambodian border,
is required.
Received August 1, 2011. Accepted for publication October 14, 2011.
Acknowledgments: We thank all patients who participated in this
study; Bounpone Phimphalat, Chanthala Vilayhong, Sengchanh
Yeuchaixiong, Manisack Phommasansack, Phanmala Baysy, Ammala
Phomsimone, Vilayphone Phanmaha, and all medical assistants and
nurses in Xepon Inter-District Hospital for their technical help;
Phaik Yeong Cheah and Prayoon Yuentrakul for acting as external
monitors; Pranom Phongmany, Sengchanh Koumphiengmaniseng,
and Deyer Gopinath for valuable advice; A. Dondorp, E. A. Ashley,
and N. P. J. Day for useful comments on the manuscript; and the
Minister of Health (Ponmek Dalaloy), the Directors of Hygiene
and Preventive Medicine (Douangchanh Keo-Asa and Bounlay
Phommasack), and the Director of Mahosot Hospital (Chanpheng
Thammavong) for support.
Financial support: This study was supported by the Bill and Melinda
Gates Foundation though World Health Organization (grant
48821.01) and World Health Organization and the Wellcome Trust
of Great Britain. Pascal Ringwald is a staff member of the World
Health Organization.
Disclaimer: The views expressed in this publication do not necessarily
representthedecisions,policy,orviewsoftheWorldHealthOrganization.
Authors’ addresses: Mayfong Mayxay, Wellcome Trust–Mahosot
Hospital–Oxford University Tropical Medicine Research Collabora-
tion, Mahosot Hospital, Vientiane, Laos, Faculty of Postgraduate
Studies, University of Health Sciences, Vientiane, Laos, and Centre
for Clinical Vaccinology and Tropical Medicine, Churchill Hospital,
Nuffield Department of Medicine, University of Oxford, Oxford OX3
7LJ, United Kingdom, E-mail: mayfong@tropmedres.ac. Maniphone
Khanthavong, Samlane Phompida, and Bouasy Hongvanthong, Centre
of Malariology, Parasitology and Entomology, Ministry of Health,
Vientiane, Laos, E-mail: cmpelao@gmail.com. Odai Chanthongthip
and Bongkot Soonthornsata, Wellcome Trust–Mahosot Hospital–
Oxford University Tropical Medicine Research Collaboration, Mahosot
Hospital, Vientiane, Laos, E-mail: kaebongkot@hotmail.com. Mallika
Imwong, Department of Molecular Tropical Medicine and Genetics,
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand,
E-mail: noi@tropmedres.ac. Sue J. Lee and Kasia Stepniewska, Centre
for Clinical Vaccinology and Tropical Medicine, Churchill Hospital,
Nuffield Department of Medicine, University of Oxford, Oxford OX3
7LJ, United Kingdom; and Faculty of Tropical Medicine, Mahidol Uni-
versity, Bangkok, Thailand, E-mails: sue@tropmedres.ac and kasia@
tropmedres.ac. Tiengkham Pongvongsa, Savannakhet Provincial Malaria
Station, Savannakhet Province, Laos, E-mail: tpongvongsa@hotmail
.com. Pascal Ringwald, Drug Resistance and Containment Unit, Global
Malaria Programme, World Health Organization, Geneva, Switzerland,
E-mail: ringwaldp@who.int. Nicholas J. White, Wellcome Trust–
Mahosot Hospital–Oxford University Tropical Medicine Research
Collaboration, Mahosot Hospital, Vientiane, Laos, Centre for Clinical
Vaccinology and Tropical Medicine, Churchill Hospital, Nuffield
Department of Medicine, University of Oxford, Oxford OX3 7LJ,
United Kingdom; and Faculty of Tropical Medicine, Mahidol Uni-
versity, Bangkok, Thailand, E-mail: nickw@tropmedres.ac. Paul N.
Newton, Wellcome Trust–Mahosot Hospital–Oxford University Tropi-
cal Medicine Research Collaboration, Mahosot Hospital, Vientiane,
Laos, Centre for Clinical Vaccinology and Tropical Medicine, Churchill
Hospital, Nuffield Department of Medicine, University of Oxford,
Oxford OX3 7LJ, United Kingdom, E-mail: paul@tropmedres.ac.
REFERENCES
1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM,
2008. Artemisinin Resistance in Cambodia 1 (ARC1) Study
Consortium. Evidence of artemisinin-resistant malaria in west-
ern Cambodia. NE n g lJM e d3 5 9 :2619–2620.
2. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D,
Ariey F, Wongsrichanalai C, 2009. Failure of artesunate-
mefloquine combination therapy for uncomplicated Plasmodium
falciparum malaria in southern Cambodia. Malar J 12: 10.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J,
Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P,
Table 3
Possible adverse events found in patients enrolled in a study
comparing 4 mg/kg/day versus 2 mg/kg/day of oral artesunate for
the treatment of Plasmodium falciparum malaria in Laos
Symptoms and signs
Before treatment
(n = 44), no. (%)
After treatment (at any time)
4 mg/kg/day
(n = 22), no. (%)
2 mg/kg/day
(n = 22), no. (%)
Weakness 43 (98) 0 1 (4.5)
Anorexia 38 (86) 1 (4.5) 3 (14)
Nausea 27 (61) 0 1 (4.5)
Vomiting 18 (41) 0 1 (4.5)
Abdominal pain 11 (25) 0 1 (4.5)
Diarrhea 7 (16) 0 1 (4.5)
Headache 44 (100) 1 (4.5) 3 (14)
Insomnia 27 (61) 1 (4.5) 1 (4.5)
Nightmares 6 (14) 0 0
Palpitations 25 (57) 0 1 (4.5)
Dyspnea 12 (27) 0 1 (4.5)
Dizziness 36 (82) 0 1 (4.5)
Vertigo 14 (32) 0 0
Tinnitus 13 (29.5) 0 0
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